385 related articles for article (PubMed ID: 34334061)
1. The role of omalizumab in the treatment of chronic rhinosinusitis with nasal polyposis.
Aldinger JP; Dobyns T; Lam K; Han JK
Expert Opin Biol Ther; 2021 Sep; 21(9):1143-1149. PubMed ID: 34334061
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Gevaert P; Omachi TA; Corren J; Mullol J; Han J; Lee SE; Kaufman D; Ligueros-Saylan M; Howard M; Zhu R; Owen R; Wong K; Islam L; Bachert C
J Allergy Clin Immunol; 2020 Sep; 146(3):595-605. PubMed ID: 32524991
[TBL] [Abstract][Full Text] [Related]
3. Biologic Therapies for Allergic Rhinitis and Nasal Polyposis.
Geng B; Dilley M; Anterasian C
Curr Allergy Asthma Rep; 2021 Jun; 21(6):36. PubMed ID: 34110505
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis.
Boyle JV; Lam K; Han JK
Immunotherapy; 2020 Feb; 12(2):111-121. PubMed ID: 32075470
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab improves sinonasal outcomes in patients with chronic rhinosinusitis with nasal polyps regardless of allergic status.
Gevaert P; Mullol J; Saenz R; Ko J; Steinke JW; Millette LA; Meltzer EO
Ann Allergy Asthma Immunol; 2024 Mar; 132(3):355-362.e1. PubMed ID: 37951571
[TBL] [Abstract][Full Text] [Related]
6. A review of phase III clinical trials of US FDA-approved biologic therapies for chronic rhinosinusitis with nasal polyposis.
Lelegren MJ; Son SY; Han JK; Lam KK
Immunotherapy; 2022 Jun; 14(8):655-662. PubMed ID: 35510314
[TBL] [Abstract][Full Text] [Related]
7. The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps.
Patel GB; Peters AT
Ear Nose Throat J; 2021 Jan; 100(1):44-47. PubMed ID: 33035132
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of switching between biologics in chronic rhinosinusitis with nasal polyps or N-ERD.
Brkic FF; Liu DT; Klimbacher R; Campion NJ; Bartosik TJ; Vyskocil E; Stanek V; Tu A; Arnoldner T; Bangert C; Gangl K; Eckl-Dorna J; Schneider S
Rhinology; 2023 Aug; 61(4):320-327. PubMed ID: 37515811
[TBL] [Abstract][Full Text] [Related]
10. A Critical Look at the Efficacy and Costs of Biologic Therapy for Chronic Rhinosinusitis with Nasal Polyposis.
Brown WC; Senior B
Curr Allergy Asthma Rep; 2020 Apr; 20(6):16. PubMed ID: 32323067
[TBL] [Abstract][Full Text] [Related]
11. Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy.
Kariyawasam HH; James LK
Drug Des Devel Ther; 2020; 14():5483-5494. PubMed ID: 33328726
[TBL] [Abstract][Full Text] [Related]
12. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis.
Rivero A; Liang J
Ann Otol Rhinol Laryngol; 2017 Nov; 126(11):739-747. PubMed ID: 28918644
[TBL] [Abstract][Full Text] [Related]
13. The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP).
Hardison SA; Senior BA
J Otolaryngol Head Neck Surg; 2023 Sep; 52(1):64. PubMed ID: 37759322
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study.
Gevaert P; Saenz R; Corren J; Han JK; Mullol J; Lee SE; Ow RA; Zhao R; Howard M; Wong K; Islam L; Ligueros-Saylan M; Omachi TA; Bachert C
J Allergy Clin Immunol; 2022 Mar; 149(3):957-965.e3. PubMed ID: 34530020
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab in chronic rhinosinusitis with nasal polyposis: current status, challenges, and future perspectives.
Li T; Yin J; Yang Y; Wang G; Zhang Y; Song X
Expert Rev Clin Immunol; 2023; 19(8):939-948. PubMed ID: 37378551
[TBL] [Abstract][Full Text] [Related]
16. Systematic literature review of the epidemiology and clinical burden of chronic rhinosinusitis with nasal polyposis.
Chen S; Zhou A; Emmanuel B; Thomas K; Guiang H
Curr Med Res Opin; 2020 Nov; 36(11):1897-1911. PubMed ID: 32847417
[TBL] [Abstract][Full Text] [Related]
17. Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis.
Damask C; Chen M; Holweg CTJ; Yoo B; Millette LA; Franzese C
Am J Rhinol Allergy; 2022 Jan; 36(1):135-141. PubMed ID: 34382434
[TBL] [Abstract][Full Text] [Related]
18. The Role of Biologics in the Treatment of Nasal Polyps.
Franzese CB
Immunol Allergy Clin North Am; 2020 May; 40(2):295-302. PubMed ID: 32278452
[TBL] [Abstract][Full Text] [Related]
19. Improvement in Smell Using Monoclonal Antibodies Among Patients With Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review.
Barroso B; Valverde-Monge M; Betancor D; Gómez-López A; Villalobos-Vilda C; González-Cano B; Sastre J
J Investig Allergol Clin Immunol; 2023 Dec; 33(6):419-430. PubMed ID: 37669083
[TBL] [Abstract][Full Text] [Related]
20. Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis.
Wu Q; Zhang Y; Kong W; Wang X; Yuan L; Zheng R; Qiu H; Huang X; Yang Q
Int Arch Allergy Immunol; 2022; 183(3):279-288. PubMed ID: 34607329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
